vs

Side-by-side financial comparison of CRYO CELL INTERNATIONAL INC (CCEL) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.

Idaho Strategic Resources, Inc. is the larger business by last-quarter revenue ($14.6M vs $7.8M, roughly 1.9× CRYO CELL INTERNATIONAL INC). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -48.7%, a 112.9% gap on every dollar of revenue. On growth, Idaho Strategic Resources, Inc. posted the faster year-over-year revenue change (92.0% vs -2.3%). Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $1.2M). Over the past eight quarters, Idaho Strategic Resources, Inc.'s revenue compounded faster (57.2% CAGR vs -0.1%).

Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

CCEL vs IDR — Head-to-Head

Bigger by revenue
IDR
IDR
1.9× larger
IDR
$14.6M
$7.8M
CCEL
Growing faster (revenue YoY)
IDR
IDR
+94.3% gap
IDR
92.0%
-2.3%
CCEL
Higher net margin
IDR
IDR
112.9% more per $
IDR
64.3%
-48.7%
CCEL
More free cash flow
IDR
IDR
$6.9M more FCF
IDR
$8.2M
$1.2M
CCEL
Faster 2-yr revenue CAGR
IDR
IDR
Annualised
IDR
57.2%
-0.1%
CCEL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCEL
CCEL
IDR
IDR
Revenue
$7.8M
$14.6M
Net Profit
$-3.8M
$9.4M
Gross Margin
77.9%
68.5%
Operating Margin
-50.6%
62.4%
Net Margin
-48.7%
64.3%
Revenue YoY
-2.3%
92.0%
Net Profit YoY
-105.1%
220.6%
EPS (diluted)
$-0.46
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCEL
CCEL
IDR
IDR
Q4 25
$7.8M
$14.6M
Q3 25
$7.8M
$11.1M
Q2 25
$7.9M
$9.5M
Q1 25
$8.0M
$7.3M
Q4 24
$8.0M
$7.6M
Q3 24
$8.1M
$6.2M
Q2 24
$8.0M
$6.1M
Q1 24
$7.9M
$5.9M
Net Profit
CCEL
CCEL
IDR
IDR
Q4 25
$-3.8M
$9.4M
Q3 25
$749.4K
$3.0M
Q2 25
$355.8K
$2.8M
Q1 25
$282.9K
$1.6M
Q4 24
$-1.9M
$2.9M
Q3 24
$1.1M
$1.6M
Q2 24
$655.8K
$2.2M
Q1 24
$556.2K
$2.2M
Gross Margin
CCEL
CCEL
IDR
IDR
Q4 25
77.9%
68.5%
Q3 25
77.0%
63.6%
Q2 25
76.6%
57.8%
Q1 25
75.1%
50.8%
Q4 24
78.4%
53.3%
Q3 24
73.6%
48.7%
Q2 24
74.8%
50.2%
Q1 24
73.7%
48.1%
Operating Margin
CCEL
CCEL
IDR
IDR
Q4 25
-50.6%
62.4%
Q3 25
24.3%
23.4%
Q2 25
18.8%
26.6%
Q1 25
13.3%
19.3%
Q4 24
-1.5%
36.2%
Q3 24
17.2%
23.4%
Q2 24
17.3%
34.2%
Q1 24
10.5%
36.3%
Net Margin
CCEL
CCEL
IDR
IDR
Q4 25
-48.7%
64.3%
Q3 25
9.6%
26.8%
Q2 25
4.5%
29.2%
Q1 25
3.5%
22.1%
Q4 24
-23.2%
38.5%
Q3 24
13.0%
25.8%
Q2 24
8.2%
35.2%
Q1 24
7.1%
36.8%
EPS (diluted)
CCEL
CCEL
IDR
IDR
Q4 25
$-0.46
$0.62
Q3 25
$0.09
$0.20
Q2 25
$0.04
$0.20
Q1 25
$0.03
$0.12
Q4 24
$-0.23
$0.21
Q3 24
$0.13
$0.12
Q2 24
$0.08
$0.17
Q1 24
$0.07
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCEL
CCEL
IDR
IDR
Cash + ST InvestmentsLiquidity on hand
$3.3M
Total DebtLower is stronger
$8.4M
$2.3M
Stockholders' EquityBook value
$-18.6M
$108.2M
Total Assets
$61.7M
$116.2M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCEL
CCEL
IDR
IDR
Q4 25
$3.3M
Q3 25
$3.2M
Q2 25
$4.4M
Q1 25
$3.5M
Q4 24
$3.5M
Q3 24
$2.1M
Q2 24
$1.5M
$6.3M
Q1 24
$979.6K
$5.3M
Total Debt
CCEL
CCEL
IDR
IDR
Q4 25
$8.4M
$2.3M
Q3 25
$8.4M
$3.0M
Q2 25
$8.4M
$3.3M
Q1 25
$8.5M
$3.7M
Q4 24
$8.5M
$1.7M
Q3 24
$8.5M
$2.9M
Q2 24
$8.5M
$2.7M
Q1 24
$8.6M
$3.3M
Stockholders' Equity
CCEL
CCEL
IDR
IDR
Q4 25
$-18.6M
$108.2M
Q3 25
$-14.8M
$74.3M
Q2 25
$-15.6M
$49.3M
Q1 25
$-14.7M
$39.8M
Q4 24
$-13.2M
$37.7M
Q3 24
$-9.6M
$33.1M
Q2 24
$-10.7M
$25.4M
Q1 24
$-10.3M
$21.6M
Total Assets
CCEL
CCEL
IDR
IDR
Q4 25
$61.7M
$116.2M
Q3 25
$63.2M
$83.1M
Q2 25
$64.4M
$57.7M
Q1 25
$64.4M
$48.1M
Q4 24
$64.7M
$44.0M
Q3 24
$62.9M
$40.8M
Q2 24
$62.6M
$32.2M
Q1 24
$61.7M
$28.7M
Debt / Equity
CCEL
CCEL
IDR
IDR
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
Q2 24
0.11×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCEL
CCEL
IDR
IDR
Operating Cash FlowLast quarter
$1.3M
$10.7M
Free Cash FlowOCF − Capex
$1.2M
$8.2M
FCF MarginFCF / Revenue
15.5%
56.0%
Capex IntensityCapex / Revenue
0.9%
17.7%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$5.2M
$12.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCEL
CCEL
IDR
IDR
Q4 25
$1.3M
$10.7M
Q3 25
$2.5M
$2.4M
Q2 25
$707.0K
$3.5M
Q1 25
$954.1K
$2.4M
Q4 24
$2.2M
$3.2M
Q3 24
$2.4M
$2.5M
Q2 24
$1.8M
$2.6M
Q1 24
$-356.9K
$2.6M
Free Cash Flow
CCEL
CCEL
IDR
IDR
Q4 25
$1.2M
$8.2M
Q3 25
$2.5M
$709.8K
Q2 25
$644.6K
$2.5M
Q1 25
$892.0K
$1.0M
Q4 24
$2.1M
$2.1M
Q3 24
$2.3M
$1.9M
Q2 24
$21.5K
$2.4M
Q1 24
$-814.6K
$2.3M
FCF Margin
CCEL
CCEL
IDR
IDR
Q4 25
15.5%
56.0%
Q3 25
31.9%
6.4%
Q2 25
8.1%
26.5%
Q1 25
11.2%
13.8%
Q4 24
26.8%
28.0%
Q3 24
27.9%
30.4%
Q2 24
0.3%
38.7%
Q1 24
-10.4%
38.3%
Capex Intensity
CCEL
CCEL
IDR
IDR
Q4 25
0.9%
17.7%
Q3 25
0.5%
15.3%
Q2 25
0.8%
10.8%
Q1 25
0.8%
19.4%
Q4 24
0.1%
13.6%
Q3 24
2.3%
9.8%
Q2 24
21.8%
4.3%
Q1 24
5.8%
5.5%
Cash Conversion
CCEL
CCEL
IDR
IDR
Q4 25
1.15×
Q3 25
3.38×
0.81×
Q2 25
1.99×
1.28×
Q1 25
3.37×
1.50×
Q4 24
1.08×
Q3 24
2.32×
1.56×
Q2 24
2.70×
1.22×
Q1 24
-0.64×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons